M
Maciej Masłyk
Researcher at John Paul II Catholic University of Lublin
Publications - 58
Citations - 972
Maciej Masłyk is an academic researcher from John Paul II Catholic University of Lublin. The author has contributed to research in topics: Steroid sulfatase & Candida albicans. The author has an hindex of 15, co-authored 50 publications receiving 602 citations. Previous affiliations of Maciej Masłyk include The Catholic University of America & CEU San Pablo University.
Papers
More filters
Journal ArticleDOI
Multitarget Anticancer Agents Based on Histone Deacetylase and Protein Kinase CK2 inhibitors.
Regina Martínez,Bruno Di Geronimo,Miryam Pastor,José María Zapico,Claire Coderch,R. R. Panchuk,N. R. Skorokhyd,Maciej Masłyk,Ana Ramos,Beatriz de Pascual-Teresa +9 more
TL;DR: The design of multi-targeting histone deacetylase (HDAC) and protein kinase CK2 inhibitors as a novel therapeutic strategy against cancer is communicated and new multitarget inhibitors have been designed and synthesized.
Journal ArticleDOI
Interactions between subunits of protein kinase CK2 and their protein substrates influences its sensitivity to specific inhibitors.
TL;DR: Both inhibitors, TBB as well as TBI, decreases cell growth to extents devoting interactions with different CK2 isoforms present in the cell but the presence of β/β′-dimer has a high importance towards sensitivity.
Journal ArticleDOI
1,4-Naphthoquinone derivatives potently suppress Candida albicans growth, inhibit formation of hyphae and show no toxicity toward zebrafish embryos.
Monika Janeczko,Konrad Kubiński,Aleksandra Martyna,Angelika Muzyczka,Anna Boguszewska-Czubara,Sławomir Czernik,Małgorzata Tokarska-Rodak,Marta Chwedczuk,Oleg M. Demchuk,Hieronim Golczyk,Maciej Masłyk +10 more
TL;DR: The research has evidenced the effectiveness of 1,4‐naphthoquinones as potential anti‐Candida agents and demonstrated the activity of these compounds against different Candida species and clinical isolates of C. albicans.
Journal ArticleDOI
Synthesis of bicoumarin thiophosphate derivatives as steroid sulfatase inhibitors.
Sebastian Demkowicz,Witold Kozak,Mateusz Daśko,Maciej Masłyk,Bartłomiej Gielniewski,Janusz Rachon +5 more
TL;DR: Most of the new STS inhibitors possessed good activities against STS, and it is found that the bis-(6-oxo-7,8,9,10-tetrahydro-6H-benzo[c]chromen-3-yl) hydrogenthiophosphate produced the largest inhibitory effect, with an IC50 value of 860 nM.
Journal ArticleDOI
Recent progress in the development of steroid sulphatase inhibitors - examples of the novel and most promising compounds from the last decade.
Mateusz Daśko,Sebastian Demkowicz,Karol Biernacki,Olga Ciupak,Witold Kozak,Maciej Masłyk,Janusz Rachon +6 more
TL;DR: Examples of novel STS inhibitors based on steroidal and nonsteroidal cores that contain various functional groups and halogen atoms are reported, which may potentially be used in therapies for hormone-dependent cancers.